Emerging Markets Regulatory Tracker: India Proposes New Trial Waiver
This article was originally published in PharmAsia News
India has recommended a waiver for certain Phase III clinical trials in the country if particular conditions are met.
You may also be interested in...
India’s health ministry has laid out basic steps towards an overhaul of drug regulation at the local level, identifying a number of areas of concern.
China has released the results of back on proposed standards for the accreditation of clinical trial committees, investigators and sites.
China has finalized revised rules for the classification of medical devices, which will come into effect from the start of next year.